3 recruiting, 2 active not recruiting, 2 completed, 1 not yet recruiting. 3 Phase 1, 2 Phase 2, 2 Phase 4, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 4 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow arexvy: new trials by email Literature Review of arexvy trials Research Report on arexvy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RSV Vaccination to Reduce Recurrent AECOPD RSV vaccination (Arexvy, GlaxoSmithKline) - COPD, RSV | Phase 4 | Not yet recruiting | Chinese University of Hong Kong | 320 | 2027-07-01 | 2026-04-13 |
| Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons Arexvy (2 doses total), Arexvy (3 doses total), Arexvy (1 dose total) - Respiratory Syncytial Virus (RSV) | Phase 2 | Recruiting | Johns Hopkins University | 170 | 2025-12-04 | 2025-12-12 |
| Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults Candidate vaccine, SCB-1019T, AREXVY, placebo - RSV Infection | Phase 1 | Recruiting | Clover Biopharmaceuticals USA, LLC | 160 | 2025-03-21 | 2025-05-14 |
| RSV Vaccine in Transplant Recipients Adjuvant, non-live RSV vaccine - Vaccine Response Impaired, Respiratory Syncytial Virus Infections | Phase 3 | Active not recruiting | University Health Network, Toronto | 100 | 2024-10-01 | 2026-05-01 |
| A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults VXB-241 60 mcg (Low Dose), VXB-241 120 mcg (Medium Dose), VXB-241 240 mcg (Medium-high Dose) - Healthy Volunteers | Phase 1 | Active not recruiting | Sanofi | 144 | 2024-08-13 | 2026-05-20 |
| A Study of IVX-A12 in Adults Participants IVX-A12, Licensed RSV Vaccine - Healthy Participants | Phase 2 | Completed | Icosavax, Inc. | 143 | 2024-06-10 | 2025-08-26 |
| First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults Candidate vaccine, SCB-1019, placebo, candidate vaccine, SCB-1019T - Respiratory Syncytial Virus Vaccination | Phase 1 | Completed | Clover Biopharmaceuticals AUS Pty | 160 | 2023-12-13 | 2025-06-06 |
| Vaccine Responses in Patients With B Cell Malignancies AREXVY, ABRYSVO, PREVNAR 20, PNEUMOVAX 23 - Lymphoma | Phase 4 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 350 | 2022-09-14 | 2026-08-04 |
Respiratory Syncytial Virus Infections (2) · Lymphoma (1) · Pulmonary Disease, Chronic Obstructive (1)
Chinese University of Hong Kong (1) · Clover Biopharmaceuticals AUS Pty (1) · Clover Biopharmaceuticals USA, LLC (1) · Icosavax, Inc. (1) · Johns Hopkins University (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Sanofi (1) · University Health Network, Toronto (1)
United States (4) · Australia (2) · Canada (1) · Hong Kong (1)
Adrian U Wiestner, M.D. (1) · Christopher Rook, MD (1) · John Baddley, MD (1) · Victoria G Hall, MBBS (1)